The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Headline
The AHA will host a webinar June 16 at 1 p.m. ET that will share insights from its Bridge to Care Toolkit, designed to help hospitals and health systems…
Headline
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022,…
Headline
 The AHA has won two Telly Awards for its three-part video series, Voices of Leadership: Breaking Mental Health Stigma. The Telly Awards, a global…
Headline
In this conversation, three leaders from CommonSpirit Health explore how the organization is confronting stigma about substance use head-on through education,…
Headline
The Health Resources and Services Administration will award grants to rural hospitals and other providers from two areas of its Rural Communities Opioid…
Perspective
Public
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable from…